Home › Research › Drug development
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah AE.. RSC advances, 2024-04-05
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer is an irreversible progressive neurodegenerative disease that causes failure of cerebral neurons and disability of the affected person to practice normal daily life activities. There is no concrete evidence to identify the exact reason behind the disease, so several relevant hypotheses emerged, highlighting many possible therapeutic targets, such as acetylcholinesterase, cholinergic receptors, N -methyl d-aspartate receptors, phosphodiesterase, amyloid β protein, protein phosphatase 2A, glycogen synthase kinase-3 beta, β-secretase, γ-secretase, α-secretase, serotonergic receptors, glutaminyl cyclase, tumor necrosis factor-α, γ-aminobutyric acid receptors, and mitochondria. All of these targets have been involved in the design of new potential drugs.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Abdallah, A. E. (2024). Review on anti-alzheimer drug development: approaches, challenges and perspectives. RSC advances. https://doi.org/10.1039/d3ra08333k
Vancouver
Abdallah AE. Review on anti-alzheimer drug development: approaches, challenges and perspectives. RSC advances. 2024. doi:10.1039/d3ra08333k. PMID: 38586442.
BibTeX
@article{abdallah2024-38586442,
author = {Abdallah, A. E.},
title = {{Review on anti-alzheimer drug development: approaches, challenges and perspectives}},
journal = {RSC advances},
year = {2024},
doi = {10.1039/d3ra08333k},
pmid = {38586442},
url = {https://doi.org/10.1039/d3ra08333k}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- There is no concrete evidence to identify the exact reason behind the disease, so several relevant hypotheses emerged, highlighting many possible therapeutic targets, such as acetylcholinesterase, cholinergic receptors, N -methyl d-aspartate receptors, phosphodiesterase, amyloid β protein, protein phosphatase 2A, glycogen synthase kinase-3 beta, β-secretase, γ-secretase, α-secretase, serotonergic receptors, glutaminyl cyclase, tumor necrosis factor-α, γ-aminobutyric acid receptors, and mitochondria.
- All of these targets have been involved in the design of new potential drugs.
- An extensive number of these drugs have been studied in clinical trials.
- However, only galantamine, donepezil, and rivastigmine (ChEIs), memantine (NMDA antagonist), and aducanumab and lecanemab (selective anti-Aβ monoclonal antibodies) have been approved for AD treatment.
Why it matters
This review states there is no concrete evidence identifying the exact cause of Alzheimer's disease, so several hypotheses have emerged pointing to many possible therapeutic targets. It notes that an extensive number of drugs have been studied in clinical trials, but only galantamine, donepezil and rivastigmine are mentioned as reaching use.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (RSC advances) |
| Journal's citation record | 3 / 4 | RSC Advances: journal h-index 286 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 63 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.8 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 15.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 3 / 4 | Cited 63 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Abdallah E. Abdallah: h-index 16 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Al-Azhar University: institution h-index 224 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38586442) |
| Free to read | 2 / 2 | Free to read |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 32.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Drug development
Also in Drug development
95 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.